Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Any participant who completed follow-up visits at 12 and 24 weeks after the last dose in one of the two predecessor studies~2. Willingness to comply with the schedule and procedures of this study.~3. Signed informed consent form (ICF).~Exclusion Criteria:~1. Participants who have had any treatment or condition (e.g., pregnancy or metabolic disease, which may lead to unstable weight) that may affect assessment of safety or efficacy since enrollment in the predecessor study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ATX-101 (Type: EXPERIMENTAL): Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
- Placebo (Type: PLACEBO_COMPARATOR): Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.

Based on this trial design, predict the completion outcome and termination type (if applicable).